BioSpace News Archive

The race is on to find a vaccine for COVID-19, the illness caused by the novel coronavirus.

Life Spine, a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spinal disorders, announced today the initiation of the PROLIFT Lateral Expandable System prospective study.

After 21 years as Arthritis Research Canada/Arthrite-recherche Canada’s scientific director, world-renowned scientist and rheumatologist, Dr. John Esdaile is handing the leadership reins over to Dr. Diane Lacaille MD,CM, MHSc, FRCPC.

ILIAS Biologics Inc. (the “Company” or “ILIAS”), a global leader in exosome-based therapeutics, announced today that the Company has been granted a key exosome engineering patent by the United States Patent and Trademark Office (USPTO).

Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” and the “Company”) today announced that the Company will host a teleconference to discuss its First Quarter 2020 financial results and to provide a business update,

EOS imaging, a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and surgical planning, announces that it has made available to the public an English translation of its Annual Financial Report as at December 31, 2019.

Dr. Leslie Fish, recently placed his 200th implant using the only FDA cleared Dental Surgical Robotics System, Yomi. This achievement makes him the most experienced Dental Robotics Surgeon in the world.

Orthopaedic surgeons at Crystal Clinic Orthopaedic Center are at the forefront of developing advanced, minimally invasive techniques for patients and providing training to other surgeons around the globe in their use.

Aesculap Implant Systems, LLC today announced that National Imaging Associates (NIA), a Magellan Health Company, has updated its “Clinical Guidelines for Medical Necessity for Musculoskeletal and Surgery” to include a medical necessity recommendation for Lumbar Total Disc Replacement (TDR), including the latest generation activL® Artificial Disc.

NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the initiation of a Phase 1/2 clinical trial for NC410, a novel immunomedicine developed to block immune suppression mediated by an immune modulator called LAIR-1.